Cargando…

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of establis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermans, Sjoerd J. F., Versluis, Jurjen, Labopin, Myriam, Giebel, Sebastian, van Norden, Yvette, Moiseev, Ivan, Blaise, Didier, Díez Martín, Jose L., Meijer, Ellen, Rovira, Montserrat, Choi, Goda, Raiola, Anna Maria, Koc, Yener, Reményi, Péter, Vydra, Jan, Kröger, Nicolaus, Sica, Simona, Martino, Massimo, van Gorkom, Gwendolyn, Chevallier, Patrice, Busca, Alessandro, Herrera Arroyo, Concepcion, Brissot, Eolia, Peric, Zinaida, Nagler, Arnon, Shouval, Roni, Ciceri, Fabio, Cornelissen, Jan J., Mohty, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946411/
https://www.ncbi.nlm.nih.gov/pubmed/36844179
http://dx.doi.org/10.1097/HS9.0000000000000846
_version_ 1784892332425871360
author Hermans, Sjoerd J. F.
Versluis, Jurjen
Labopin, Myriam
Giebel, Sebastian
van Norden, Yvette
Moiseev, Ivan
Blaise, Didier
Díez Martín, Jose L.
Meijer, Ellen
Rovira, Montserrat
Choi, Goda
Raiola, Anna Maria
Koc, Yener
Reményi, Péter
Vydra, Jan
Kröger, Nicolaus
Sica, Simona
Martino, Massimo
van Gorkom, Gwendolyn
Chevallier, Patrice
Busca, Alessandro
Herrera Arroyo, Concepcion
Brissot, Eolia
Peric, Zinaida
Nagler, Arnon
Shouval, Roni
Ciceri, Fabio
Cornelissen, Jan J.
Mohty, Mohamad
author_facet Hermans, Sjoerd J. F.
Versluis, Jurjen
Labopin, Myriam
Giebel, Sebastian
van Norden, Yvette
Moiseev, Ivan
Blaise, Didier
Díez Martín, Jose L.
Meijer, Ellen
Rovira, Montserrat
Choi, Goda
Raiola, Anna Maria
Koc, Yener
Reményi, Péter
Vydra, Jan
Kröger, Nicolaus
Sica, Simona
Martino, Massimo
van Gorkom, Gwendolyn
Chevallier, Patrice
Busca, Alessandro
Herrera Arroyo, Concepcion
Brissot, Eolia
Peric, Zinaida
Nagler, Arnon
Shouval, Roni
Ciceri, Fabio
Cornelissen, Jan J.
Mohty, Mohamad
author_sort Hermans, Sjoerd J. F.
collection PubMed
description Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of established NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, and subsequently developed and validated a novel PTCY-specific NRM-risk model. Adult patients (n = 1861) with AML or ALL in first complete remission who received alloSCT with PTCY-based GVHD prophylaxis were included. The PTCY-risk score was developed using multivariable Fine and Gray regression, selecting parameters from the hematopoietic cell transplantation-comorbidity index (HCT-CI) and European Group for Blood and Marrow Transplantation (EBMT) score with a subdistribution hazard ratio (SHR) of ≥1.2 for 2-year NRM in the training set (70% split), which was validated in the test set (30%). The performance of the EBMT score, HCT-CI, and integrated EBMT score was relatively poor for discriminating 2-year NRM (c-statistic 51.7%, 56.6%, and 59.2%, respectively). The PTCY-risk score included 10 variables which were collapsed in 3 risk groups estimating 2-year NRM of 11% ± 2%, 19% ± 2%, and 36% ± 3% (training set, c-statistic 64%), and 11% ± 2%, 18% ± 3%, and 31% ± 5% (test set, c-statistic 63%), which also translated into different overall survival. Collectively, we developed an NRM-risk score for acute leukemia patients receiving PTCY that better predicted 2-year NRM compared with existing models, which might be applicable to the specific toxicities of high-dose cyclophosphamide.
format Online
Article
Text
id pubmed-9946411
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99464112023-02-23 Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis Hermans, Sjoerd J. F. Versluis, Jurjen Labopin, Myriam Giebel, Sebastian van Norden, Yvette Moiseev, Ivan Blaise, Didier Díez Martín, Jose L. Meijer, Ellen Rovira, Montserrat Choi, Goda Raiola, Anna Maria Koc, Yener Reményi, Péter Vydra, Jan Kröger, Nicolaus Sica, Simona Martino, Massimo van Gorkom, Gwendolyn Chevallier, Patrice Busca, Alessandro Herrera Arroyo, Concepcion Brissot, Eolia Peric, Zinaida Nagler, Arnon Shouval, Roni Ciceri, Fabio Cornelissen, Jan J. Mohty, Mohamad Hemasphere Article Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of established NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, and subsequently developed and validated a novel PTCY-specific NRM-risk model. Adult patients (n = 1861) with AML or ALL in first complete remission who received alloSCT with PTCY-based GVHD prophylaxis were included. The PTCY-risk score was developed using multivariable Fine and Gray regression, selecting parameters from the hematopoietic cell transplantation-comorbidity index (HCT-CI) and European Group for Blood and Marrow Transplantation (EBMT) score with a subdistribution hazard ratio (SHR) of ≥1.2 for 2-year NRM in the training set (70% split), which was validated in the test set (30%). The performance of the EBMT score, HCT-CI, and integrated EBMT score was relatively poor for discriminating 2-year NRM (c-statistic 51.7%, 56.6%, and 59.2%, respectively). The PTCY-risk score included 10 variables which were collapsed in 3 risk groups estimating 2-year NRM of 11% ± 2%, 19% ± 2%, and 36% ± 3% (training set, c-statistic 64%), and 11% ± 2%, 18% ± 3%, and 31% ± 5% (test set, c-statistic 63%), which also translated into different overall survival. Collectively, we developed an NRM-risk score for acute leukemia patients receiving PTCY that better predicted 2-year NRM compared with existing models, which might be applicable to the specific toxicities of high-dose cyclophosphamide. Lippincott Williams & Wilkins 2023-02-21 /pmc/articles/PMC9946411/ /pubmed/36844179 http://dx.doi.org/10.1097/HS9.0000000000000846 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Hermans, Sjoerd J. F.
Versluis, Jurjen
Labopin, Myriam
Giebel, Sebastian
van Norden, Yvette
Moiseev, Ivan
Blaise, Didier
Díez Martín, Jose L.
Meijer, Ellen
Rovira, Montserrat
Choi, Goda
Raiola, Anna Maria
Koc, Yener
Reményi, Péter
Vydra, Jan
Kröger, Nicolaus
Sica, Simona
Martino, Massimo
van Gorkom, Gwendolyn
Chevallier, Patrice
Busca, Alessandro
Herrera Arroyo, Concepcion
Brissot, Eolia
Peric, Zinaida
Nagler, Arnon
Shouval, Roni
Ciceri, Fabio
Cornelissen, Jan J.
Mohty, Mohamad
Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title_full Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title_fullStr Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title_full_unstemmed Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title_short Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
title_sort prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946411/
https://www.ncbi.nlm.nih.gov/pubmed/36844179
http://dx.doi.org/10.1097/HS9.0000000000000846
work_keys_str_mv AT hermanssjoerdjf predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT versluisjurjen predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT labopinmyriam predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT giebelsebastian predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT vannordenyvette predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT moiseevivan predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT blaisedidier predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT diezmartinjosel predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT meijerellen predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT roviramontserrat predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT choigoda predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT raiolaannamaria predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT kocyener predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT remenyipeter predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT vydrajan predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT krogernicolaus predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT sicasimona predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT martinomassimo predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT vangorkomgwendolyn predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT chevallierpatrice predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT buscaalessandro predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT herreraarroyoconcepcion predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT brissoteolia predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT periczinaida predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT naglerarnon predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT shouvalroni predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT cicerifabio predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT cornelissenjanj predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis
AT mohtymohamad predictionofnonrelapsemortalityinpatientswithacutemyeloidleukemiaandacutelymphoblasticleukemiareceivingallogeneicstemcelltransplantationwithposttransplantationcyclophosphamidebasedgraftversushostdiseaseprophylaxis